Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integrating HIV services in an era of global change.

Journal of the International AIDS Society·2026

Same author

A national cross-sectional analysis of surveillance drug resistance mutations among recently diagnosed antiretroviral naïve Brazilian people with HIV.

Lancet regional health. Americas·2025

Same author

Deep Vein Thrombosis in Critically Ill Patients With COVID-19 Pneumonia: Incidence, Wells Score Diagnostic Performance, and Hospital Prognosis.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2025

Same author

Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV.

The Journal of infectious diseases·2025

Same author

Metabolic dysfunction-associated liver disease predicts incident liver fibrosis in people with HIV mono-infection: A cohort study.

HIV medicine·2025

Same author

Metabolic dysfunction-associated steatotic liver disease was associated with liver fibrosis in people with HIV from Brazil.

AIDS (London, England)·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Monotherapy with lopinavir/ritonavir.

Mauro Schechter¹, Estevão Portela Nunes

¹Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Brazil. maurosch@hucff.ufrj.br

Expert Opinion on Investigational Drugs

|April 28, 2007

Summary

Lopinavir/ritonavir monotherapy shows promise for simplifying HIV treatment, offering a potentially cost-effective option. Further research is needed to confirm its long-term efficacy and safety, especially in resource-limited settings.

Area of Science:

Virology
Pharmacology
Infectious Diseases

Background:

Antiretroviral therapy (ART) has significantly improved HIV treatment outcomes.
There is an ongoing need for simpler, less toxic, and more affordable HIV treatment regimens.
Boosted protease inhibitors possess favorable pharmacokinetic profiles and high genetic barriers, suggesting potential for monotherapy.

Purpose of the Study:

To evaluate the potential of lopinavir/ritonavir monotherapy as a simplified HIV treatment strategy.
To explore the cost-effectiveness of lopinavir/ritonavir monotherapy for second-line therapy in resource-constrained settings.
To identify areas for further investigation regarding the long-term efficacy and safety of protease inhibitor monotherapy.

Main Methods:

Review of available studies on lopinavir/ritonavir monotherapy in patients without prior protease inhibitor failure.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jul 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Consideration of pharmacokinetic profiles and genetic barrier data for boosted protease inhibitors.

Proposal for future clinical trials focusing on cost-effectiveness and long-term outcomes.

Main Results:

Lopinavir/ritonavir monotherapy has shown encouraging results in preliminary studies.
The pharmacokinetic properties and high genetic barrier of lopinavir/ritonavir support its consideration for monotherapy.
Further investigation is warranted, particularly in resource-limited settings.

Conclusions:

Lopinavir/ritonavir monotherapy may offer a viable option for simplifying HIV treatment, especially as second-line therapy.
Cost-effectiveness studies in resource-limited settings are needed.
Larger trials with extended follow-up are essential to assess long-term efficacy and potential risks, including viral replication in specific body sites.